Literature DB >> 12789923

Origin of adenocarcinoma cells observed on cervical cytology.

Motoi Sasagawa1, Koji Nishino, Shigeru Honma, Shoji Kodama, Takeshi Takahashi.   

Abstract

OBJECTIVE: To clarify the ratio of diseases suspected when malignant glandular cells are observed on cervical cytology. STUDY
DESIGN: Seventy cases of cervical adenocarcinoma/adenosquamous carcinoma, 207 cases of endometrial adenocarcinoma, 7 cases of tubal adenocarcinoma and 83 cases of ovarian adenocarcinoma were reviewed. The positive rate in cervical cytology performed 3 months before surgery was calculated. Based on the positive rate for each entity and the number of cases treated in the previous 10 years, we estimated the incidence of disease responsible for malignant glandular cells on cytology.
RESULTS: The positive rate was 93% in cervical adenocarcinoma/adenosquamous carcinoma, 45% in endometrial adenocarcinoma, 14% in tubal adenocarcinoma and 6% in ovarian adenocarcinoma. These positive rates and case numbers at our institute indicated the percentage of suspicious diseases to be 38% for cervical aaenocarcinoma/adenosquamous carcinoma, 53% for endometrial adenocarcinoma, 1% for tubal adenocarcinoma and 8% for ovarian adenocarcinoma.
CONCLUSION: When a cytologic specimen suggested the existence of adenocarcinoma, the most probable disease was endometrial adenocarcinoma, and the second was cervical adenocarcinoma/adenosquamous carcinoma. Adnexal malignancies were responsible in 9% of cases. In the case of positive cervical cytology suggesting adenocarcinoma, the ratio of suspicious diseases is as valuable as the cytologic findings for the differential diagnosis.

Entities:  

Mesh:

Year:  2003        PMID: 12789923     DOI: 10.1159/000326542

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  1 in total

1.  Cytologic findings of cervicovaginal smears in women with uterine papillary serous carcinoma.

Authors:  Ji-Young Park; Hye Sun Kim; Sung Ran Hong; Yi Kyeong Chun
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.